ProQR Therapeutics NVNASDAQ:PRQR
- LAST PRICE3.4700
- TODAY'S CHANGE (%)-0.0700 (-1.9774%)
- Bid / Lots3.4600/ 2
- Ask / Lots3.5000/ 6
- Open / Previous Close3.5400 / 3.5400
- Day Range
- 52 Week Range
- Volume60,929
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PRQR |
|---|---|---|
| 09:32 ET | 3855 | 3.52 |
| 09:33 ET | 427 | 3.5348 |
| 09:35 ET | 13413 | 3.5 |
| 09:39 ET | 400 | 3.48 |
| 09:42 ET | 100 | 3.51 |
| 09:44 ET | 100 | 3.525 |
| 09:46 ET | 2000 | 3.525 |
| 09:50 ET | 100 | 3.525 |
| 09:51 ET | 400 | 3.525 |
| 09:57 ET | 100 | 3.52 |
| 10:00 ET | 15131 | 3.465 |
| 10:02 ET | 6000 | 3.48 |
| 10:04 ET | 11300 | 3.4701 |
| 10:06 ET | 3918 | 3.47 |
Nov 8, 2024
DJ ProQR Therapeutics Is Maintained at Buy by HC Wainwright & Co., from 7:44AM ET on Friday Nov 08, 2024 by Dow Jones
7:44AM ET on Friday Nov 08, 2024 by Dow Jones
Nov 7, 2024
*DJ ProQR Therapeutics 3Q Rev EUR3.84M >PRQR, from 7:01AM ET on Thursday Nov 07, 2024 by Dow Jones
7:01AM ET on Thursday Nov 07, 2024 by Dow JonesProQR Announces Third Quarter 2024 Operating and Financial Results, from 7:00AM ET on Thursday Nov 07, 2024 by Dow Jones
7:00AM ET on Thursday Nov 07, 2024 by Dow Jones
Oct 29, 2024
DJ ProQR Therapeutics Raised to Strong Buy From Outperform by Raymond James, from 9:38AM ET on Tuesday Oct 29, 2024 by Dow Jones
9:38AM ET on Tuesday Oct 29, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
ProQR Therapeutics NV | 383.4M | -11.3x | --- |
Verve Therapeutics Inc | 410.6M | -2.1x | --- |
4D Molecular Therapeutics Inc | 404.8M | -2.8x | --- |
Larimar Therapeutics Inc | 393.0M | -5.5x | --- |
AC Immune SA | 334.4M | -7.3x | --- |
XOMA Royalty Corp | 355.8M | -10.2x | --- |
Company Information
ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).
Contact Information
- Headquarters
- Zernikedreef 9LEIDEN, Netherlands 2333 CK
- Phone
- ---
- Fax
- ---
Executives
- Independent Non-Executive Chairman of the Board
- James Shannon
- Chief Executive Officer, Founder, Executive Director
- Daniel De Boer
- Chief Financial Officer
- Jurriaan Dekkers
- Chief People and Operations Officer
- Sheila Sponselee
- Chief Scientific Officer, Executive Director
- Gerard Platenburg
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $383.4M |
|---|---|
Revenue (TTM) | $22.4M |
Shares Outstanding | 105.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.22 |
EPS | $-0.31 |
Book Value | $0.52 |
P/E Ratio | -11.3x |
Price/Sales (TTM) | 17.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -125.49% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
